Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 1 (January)

1. Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
   Am J Surg Pathol, 31(1): 129-40. [Abstract] [Full-text]
2. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
   Am J Surg Pathol, 31(1): 121-8. [Abstract] [Full-text]
3. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
   J Surg Oncol, 95(1): 45-50. [Abstract] [Full-text]
4. Prognostic markers in triple-negative breast cancer.
   Cancer, 109(1): 25-32. [Abstract] [Full-text]
5. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer.
   Tumour Biol, 28(1): 36-44. [Abstract] [Full-text]
6. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy.
   Cancer, 109(1): 146-56. [Abstract] [Full-text]
7. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells.
   Mol Carcinog, 46(1): 71-84. [Abstract] [Full-text]
8. IGF-1 upregulates electroneutral K-Cl cotransporter KCC3 and KCC4 which are differentially required for breast cancer cell proliferation and invasiveness.
   J Cell Physiol, 210(3): 626-36. [Abstract] [Full-text]
9. Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3.
   Genes Chromosomes Cancer, 46(3): 302-9. [Abstract] [Full-text]
10. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
    Genes Chromosomes Cancer, 46(3): 288-301. [Abstract] [Full-text]
11. Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman.
    Pathol Int, 57(1): 43-6. [Abstract] [Full-text]
12. Statins and the risk of lung, breast, and colorectal cancer in the elderly.
    Circulation, 115(1): 27-33. [Abstract] [Full-text]
13. Folate and risk of breast cancer: a meta-analysis.
    J Natl Cancer Inst, 99(1): 64-76. [Abstract] [Full-text]
14. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Lancet, 369(9555): 29-36. [Abstract] [Full-text]
15. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
    J Med Genet, 44(1): 10-15. [Abstract] [Full-text]
16. Interpreting the economic literature in oncology.
    J Clin Oncol, 25(2): 196-202. [Abstract] [Full-text]
17. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Cancer Res, 67(1): 391-7. [Abstract] [Full-text]
18. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
    Cancer Res, 67(1): 289-99. [Abstract] [Full-text]
19. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Cancer Res, 67(1): 9-15. [Abstract] [Full-text]
20. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review.
    Am J Epidemiol, 165(2): 115-25. [Abstract] [Full-text]
21. Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
    Biochem J, 401(3): 689-99. [Abstract] [Full-text]
22. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5.
    Exp Mol Pathol, 82(1): 25-32. [Abstract] [Full-text]
23. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
    Exp Mol Pathol, 82(1): 85-90. [Abstract] [Full-text]
24. Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species.
    Exp Mol Pathol, 82(1): 1-11. [Abstract] [Full-text]
25. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments.
    Brain Behav Immun, 21(2): 185-94. [Abstract] [Full-text]
26. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.
    Oncogene, 26(2): 290-7. [Abstract] [Full-text]
27. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer.
    Oncogene, 26(2): 298-307. [Abstract] [Full-text]
28. Improving the quality and efficiency of follow-up after curative treatment for breast cancer--rationale and study design of the MaCare trial.
    BMC Cancer, 7: 1. [Abstract] [Full-text]
29. Doxorubicin down-regulates Kruppel-associated box domain-associated protein 1 sumoylation that relieves its transcription repression on p21WAF1/CIP1 in breast cancer MCF-7 cells.
    J Biol Chem, 282(3): 1595-606. [Abstract] [Full-text]
30. How women with breast cancer learn using interactive cancer communication systems.
    Health Educ Res, 22(1): 108-19. [Abstract] [Full-text]
31. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
    Maturitas, 56(2): 142-52. [Abstract] [Full-text]
32. Surgeon characteristics and variations in treatment for early-stage breast cancer.
    Arch Surg, 142(1): 17-22. [Abstract] [Full-text]
33. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
    Anaesthesia, 62(2): 186-9. [Abstract] [Full-text]
34. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
    Cancer Chemother Pharmacol, 59(4): 515-25. [Abstract] [Full-text]
35. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    J Natl Cancer Inst, 99(2): 167-70. [Abstract] [Full-text]
36. An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy.
    BMC Cancer, 6: 298. [Abstract] [Full-text]
37. Mammographic density and the risk and detection of breast cancer.
    N Engl J Med, 356(3): 227-36. [Abstract] [Full-text]
38. The prognostic role of a gene signature from tumorigenic breast-cancer cells.
    N Engl J Med, 356(3): 217-26. [Abstract] [Full-text]
39. Reliability and validity testing of the Patient and Observer Scar Assessment Scale in evaluating linear scars after breast cancer surgery.
    Plast Reconstr Surg, 119(2): 487-94. [Abstract] [Full-text]
40. Breast reconstruction following mastectomy for breast cancer: the decisions of sexual minority women.
    Plast Reconstr Surg, 119(2): 464-72. [Abstract] [Full-text]
41. Patterns and correlates of patient referral to surgeons for treatment of breast cancer.
    J Clin Oncol, 25(3): 271-6. [Abstract] [Full-text]
42. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    J Clin Oncol, 25(3): 263-70. [Abstract] [Full-text]
43. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    J Clin Oncol, 25(3): 292-300. [Abstract] [Full-text]
44. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    J Clin Oncol, 25(3): 285-91. [Abstract] [Full-text]
45. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.
    J Clin Oncol, 25(3): 277-84. [Abstract] [Full-text]
46. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Hum Pathol, 38(2): 197-204. [Abstract] [Full-text]
47. Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells.
    Cancer Sci, 98(2): 174-81. [Abstract] [Full-text]
48. TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression.
    Hum Pathol, 38(2): 293-8. [Abstract] [Full-text]
49. Characterization of columnar cell lesions of the breast: immunophenotypic analysis of columnar alteration of lobules with prominent apical snouts and secretions.
    Hum Pathol, 38(2): 284-92. [Abstract] [Full-text]
50. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance.
    Hum Pathol, 38(2): 247-59. [Abstract] [Full-text]
51. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis.
    Int J Radiat Oncol Biol Phys, 67(2): 490-6. [Abstract] [Full-text]
52. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers.
    Br J Cancer, 96(2): 352-6. [Abstract] [Full-text]
53. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.
    Br J Cancer, 96(2): 329-35. [Abstract] [Full-text]
54. Image quality of digital direct flat-panel mammography versus an analog screen-film technique using a phantom model.
    AJR Am J Roentgenol, 188(2): 399-407. [Abstract] [Full-text]
55. Factors associated with imaging and procedural events used to detect breast cancer after screening mammography.
    AJR Am J Roentgenol, 188(2): 385-92. [Abstract] [Full-text]
56. Effect of computer-aided detection on independent double reading of paired screen-film and full-field digital screening mammograms.
    AJR Am J Roentgenol, 188(2): 377-84. [Abstract] [Full-text]
57. Effects on breast MRI of artifacts caused by metallic tissue marker clips.
    AJR Am J Roentgenol, 188(2): 372-6. [Abstract] [Full-text]
58. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.
    Br J Cancer, 96(2): 241-7. [Abstract] [Full-text]
59. Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis.
    Br J Cancer, 96(2): 248-54. [Abstract] [Full-text]
60. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
    Br J Cancer, 96(2): 341-51. [Abstract] [Full-text]
61. A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy.
    Ann Surg, 245(2): 290-6. [Abstract] [Full-text]
62. Cytologic diagnosis of columnar-cell lesions of the breast.
    Diagn Cytopathol, 35(2): 73-9. [Abstract] [Full-text]
63. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Nature, 445(7126): 437-41. [Abstract] [Full-text]
64. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates.
    Cancer, 109(3): 487-95. [Abstract] [Full-text]
65. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Cancer, 109(3): 496-501. [Abstract] [Full-text]
66. Pathogenesis and vascular integrity of breast cancer brain metastasis.
    Int J Cancer, 120(5): 1023-6. [Abstract] [Full-text]
67. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
    Int J Cancer, 120(5): 1013-22. [Abstract] [Full-text]
68. Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer.
    Int J Cancer, 120(5): 1087-92. [Abstract] [Full-text]
69. Breast cancer mortality after screening mammography in British Columbia women.
    Int J Cancer, 120(5): 1076-80. [Abstract] [Full-text]
70. Prediction of metastasis from low-malignant breast cancer by gene expression profiling.
    Int J Cancer, 120(5): 1070-5. [Abstract] [Full-text]
71. Breast cancer guidelines--Physicians' intentions and behaviors.
    Int J Cancer, 120(5): 1136-40. [Abstract] [Full-text]
72. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
    Am J Surg Pathol, 31(2): 247-54. [Abstract] [Full-text]
73. Use of microcalcification descriptors in BI-RADS 4th edition to stratify risk of malignancy.
    Radiology, 242(2): 388-95. [Abstract] [Full-text]
74. Pregnancy after breast cancer: population based study.
    BMJ, 334(7586): 194. [Abstract] [Full-text]
75. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells.
    Biochem Biophys Res Commun, 354(1): 165-71. [Abstract] [Full-text]
76. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery.
    Biomaterials, 28(10): 1889-99. [Abstract] [Full-text]
77. Strategies in treating male breast cancer.
    Expert Opin Pharmacother, 8(2): 193-202. [Abstract] [Full-text]
78. Pharmacogenetics and oncology treatment for breast cancer.
    Expert Opin Pharmacother, 8(2): 119-27. [Abstract] [Full-text]
79. Stress, optimism, and social support: impact on immune responses in breast cancer.
    Res Nurs Health, 30(1): 72-83. [Abstract] [Full-text]
80. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Mol Endocrinol, 21(2): 439-56. [Abstract] [Full-text]
81. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    J Clin Oncol, 25(4): 405-10. [Abstract] [Full-text]
82. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    J Clin Oncol, 25(4): 411-7. [Abstract] [Full-text]
83. A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer.
    BMC Cancer, 7: 14. [Abstract] [Full-text]
84. Localised breast cancers may have systemic influences on skin and hair.
    J Clin Pathol, 60(2): 180-4. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.